Equities

Prothena Corporation PLC

Prothena Corporation PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)21.48
  • Today's Change-0.46 / -2.10%
  • Shares traded586.48k
  • 1 Year change-59.10%
  • Beta0.1815
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

  • Revenue in USD (TTM)217.25m
  • Net income in USD-50.92m
  • Incorporated2012
  • Employees173.00
  • Location
    Prothena Corporation PLC77 Sir John Rogersons QuayBlock C, Grand Canal DocklandsDUBLIN D02 T804IrelandIRL
  • Phone+353 12362500
  • Fax+353 19023510
  • Websitehttps://www.prothena.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CARGO Therapeutics Inc0.00-147.71m1.07bn116.00--2.45-----3.47-3.470.009.510.00----0.00-53.66---59.56--------------0.00-------139.67------
Longboard Pharmaceuticals Inc0.00-64.74m1.07bn50.00--3.64-----2.16-2.160.007.580.00----0.00-34.15---36.32--------------0.00-------23.84------
Vir Biotechnology Inc78.88m-483.04m1.08bn587.00--0.7555--13.74-3.58-3.580.583810.500.0403----134,373.10-24.69-0.6081-26.90-0.719298.80---612.40-1.53----0.00---94.6751.87-219.24--16.77--
Pharvaris NV0.00-126.79m1.09bn82.00--2.96-----2.66-2.660.006.850.00----0.00-42.13-36.09-45.04-38.27------------0.0004-------32.15------
Travere Therapeutics Inc177.64m-383.45m1.10bn380.00--72.69--6.20-4.99-1.882.310.19810.27590.76137.92467,484.20-59.56-36.95-74.41-44.7794.7095.92-215.85-165.792.99--0.9615--32.69-2.43-13.54--16.49--
Phathom Pharmaceuticals Inc9.92m-297.11m1.10bn452.00------111.10-5.13-5.130.1717-3.990.03391.72--21,942.48-101.68-83.26-115.19-93.7780.15---2,995.68-135,982.006.44-5.741.86-------1.96------
AnaptysBio Inc30.47m-170.12m1.13bn117.00--104.14--37.15-6.34-6.341.140.36010.0645--5.00260,453.00-36.02-18.08-39.45-18.96-----558.25-269.21----0.00--66.7827.97-27.11---5.36--
Cogent Biosciences Inc0.00-227.05m1.15bn164.00--4.44-----2.48-2.480.003.410.00----0.00-55.22-49.53-60.02-54.94-------1,684.44----0.00-------37.20--38.48--
Prothena Corporation PLC217.25m-50.92m1.18bn173.00--2.03--5.43-1.01-1.013.9410.820.318--829.181,255,757.00-7.45-14.20-8.16-15.11-----23.44-111.02----0.00--69.50148.98-25.72--9.71--
Tyra Biosciences Inc0.00-80.88m1.18bn49.00--3.14-----1.69-1.690.007.130.00----0.00-25.18---25.81--------------0.00-------24.96------
Day One Biopharmaceuticals Inc8.19m-167.48m1.21bn169.00--3.93--147.41-1.94-1.940.09483.500.0193----52,851.61-39.35---45.70--91.37---2,044.43--4.09--0.00-------32.87------
Arcutis Biotherapeutics Inc132.06m-198.76m1.21bn296.00--6.48--9.18-2.18-2.181.361.600.34510.83344.36446,155.40-51.93-65.64-58.68-71.7292.32---150.51-1,513.038.19-5.940.5223--1,517.09--15.83------
Relay Therapeutics Inc35.21m-322.83m1.23bn304.00--1.49--34.95-2.52-2.520.2775.110.0406----109,003.10-37.22-28.55-39.91-29.54-----916.92-998.20----0.00--1,749.82---17.72--19.59--
ARS Pharmaceuticals Inc500.00k-44.84m1.27bn23.00--5.88--2,530.18-0.466-0.4660.00522.220.0021----20,833.33-18.66-20.37-19.33-21.32-----8,968.40-17,491.75----0.00---97.72---56.75---17.18--
Data as of Sep 18 2024. Currency figures normalised to Prothena Corporation PLC's reporting currency: US Dollar USD

Institutional shareholders

70.42%Per cent of shares held by top holders
HolderShares% Held
EcoR1 Capital, LLCas of 30 Jun 202411.58m21.54%
Fidelity Management & Research Co. LLCas of 30 Jun 20248.07m15.00%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 20244.16m7.74%
Wellington Management Co. LLPas of 30 Jun 20243.58m6.66%
BlackRock Fund Advisorsas of 30 Jun 20243.24m6.03%
SSgA Funds Management, Inc.as of 30 Jun 20241.93m3.59%
Palo Alto Investors LPas of 30 Jun 20241.67m3.10%
Armistice Capital LLCas of 30 Jun 20241.56m2.90%
The Vanguard Group, Inc.as of 30 Jun 20241.07m1.99%
Janus Henderson Investors US LLCas of 30 Jun 20241.01m1.87%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.